secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001683168-25-002355
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio gets SMC nod to advance PH-762 skin cancer trial to 4th dose cohort
------------------------------------------------------------------------

- Safety Monitoring Committee recommended dose escalation to fourth cohort in Phase 1b trial (NCT06014086).
- Third cohort (3 patients with cutaneous squamous cell carcinoma): no serious AEs, no dose-limiting toxicities.
- Prior second cohort (4 patients): 2 complete responses (100% tumor clearance), 1 partial (90% clearance) at Day 36.
- PH-762 is an intratumoral siRNA compound targeting cutaneous SCC, melanoma, and Merkel cell carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825002355/0001683168-25-002355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825002355/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-002355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer